{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:06:16Z","timestamp":1780481176789,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA033934"],"award-info":[{"award-number":["P30DA033934"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005289","name":"National Institute of Justice","doi-asserted-by":"publisher","award":["2019-R2-CX-0046"],"award-info":[{"award-number":["2019-R2-CX-0046"]}],"id":[{"id":"10.13039\/100005289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00213-022-06093-w","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T17:02:55Z","timestamp":1645722175000},"page":"2187-2199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Opioid-like adverse effects of tianeptine in male rats and mice"],"prefix":"10.1007","volume":"239","author":[{"given":"T. R.","family":"Baird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. I.","family":"Akbarali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. L.","family":"Dewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Peace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Poklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8471-645X","authenticated-orcid":false,"given":"S. S.","family":"Negus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"issue":"4","key":"6093_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00213-005-0210-5","volume":"183","author":"T Alici","year":"2006","unstructured":"Alici T, Kayir H, Aygoren MO, Saglam E, Uzbay IT (2006) Discriminative stimulus properties of tianeptine. Psychopharmacology 183(4):446\u2013451. https:\/\/doi.org\/10.1007\/s00213-005-0210-5","journal-title":"Psychopharmacology"},{"issue":"6","key":"6093_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1177\/0269881116689257","volume":"31","author":"AA Altarifi","year":"2017","unstructured":"Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS (2017) Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol 31(6):730\u2013739. https:\/\/doi.org\/10.1177\/0269881116689257","journal-title":"J Psychopharmacol"},{"issue":"7","key":"6093_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/FBP.0b013e328358593c","volume":"23","author":"AA Altarifi","year":"2012","unstructured":"Altarifi AA, Miller LL, Stevens Negus S (2012) Role of \u00b5-opioid receptor reserve and \u00b5-agonist efficacy as determinants of the effects of \u00b5-agonists on intracranial self-stimulation in rats. Behav Pharmacol 23(7):678\u2013692. https:\/\/doi.org\/10.1097\/FBP.0b013e328358593c","journal-title":"Behav Pharmacol"},{"key":"6093_CR4","doi-asserted-by":"publisher","unstructured":"Altarifi AA, Moerke MJ, Alsalem MI,\u00a0 Negus SS (2020) Preclinical assessment of tramadol abuse potential: effects of acute and repeated tramadol on intracranial self-stimulation in rats. J Psychopharmacol\u00a010. https:\/\/doi.org\/10.1177\/0269881120944153","DOI":"10.1177\/0269881120944153"},{"issue":"7","key":"6093_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FBP.0b013e32834aff54","volume":"22","author":"AA Altarifi","year":"2011","unstructured":"Altarifi AA, Negus SS (2011) Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence. Behav Pharmacol 22(7):663\u2013673. https:\/\/doi.org\/10.1097\/FBP.0b013e32834aff54","journal-title":"Behav Pharmacol"},{"issue":"5 and 6","key":"6093_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/FBP.0b013e328364c0bd","volume":"24","author":"AA Altarifi","year":"2013","unstructured":"Altarifi AA, Rice KC, Negus SS (2013) Abuse-related effects of \u00b5-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure. Behavioural Pharmacology 24(5 and 6):459\u2013470. https:\/\/doi.org\/10.1097\/FBP.0b013e328364c0bd","journal-title":"Behavioural Pharmacology"},{"key":"6093_CR7","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.etdah.2021.100004","volume":"1","author":"TR Baird","year":"2021","unstructured":"Baird TR, Davies RA, Glennon RA, Peace MR, Negus SS (2021) A strategy to prioritize emerging drugs of abuse for analysis: abuse liability testing using intracranial self-stimulation (ICSS) in rats and validation with \u03b1-pyrrolidinohexanophenone (\u03b1-PHP). Emerging Trends in Drugs, Addictions, and Health 1:100004. https:\/\/doi.org\/10.1016\/j.etdah.2021.100004","journal-title":"Emerging Trends in Drugs, Addictions, and Health"},{"issue":"7","key":"6093_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jat\/bky023","volume":"42","author":"EL Bakota","year":"2018","unstructured":"Bakota EL, Samms WC, Gray TR, Oleske DA, Hines MO (2018) Case reports of fatalities involving tianeptine in the United States. J Anal Toxicol 42(7):503\u2013509. https:\/\/doi.org\/10.1093\/jat\/bky023","journal-title":"J Anal Toxicol"},{"issue":"12","key":"6093_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.tips.2018.09.006","volume":"39","author":"MH Baumann","year":"2018","unstructured":"Baumann MH, Kopajtic TA, Madras BK (2018) Pharmacological research as a key component in mitigating the opioid overdose crisis. Trends Pharmacol Sci 39(12):995\u2013998. https:\/\/doi.org\/10.1016\/j.tips.2018.09.006","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"6093_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/JCP.0b013e3182217a50","volume":"31","author":"K Bernard","year":"2011","unstructured":"Bernard K, Penelaud P-F, Moca\u00ebr E, Donazzolo Y (2011) Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers. J Clin Psychopharmacol 31(4):441\u2013448. https:\/\/doi.org\/10.1097\/JCP.0b013e3182217a50","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"6093_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.phrs.2008.03.006","volume":"57","author":"VN Bolton","year":"2008","unstructured":"Bolton VN, Bassil AK, Lee K, Sanger GJ (2008) Inhibition by tianeptine of neuronally mediated contractions in the rat isolated gastrointestinal tract. Pharmacol Res 57(5):339\u2013343. https:\/\/doi.org\/10.1016\/j.phrs.2008.03.006","journal-title":"Pharmacol Res"},{"key":"6093_CR12","doi-asserted-by":"publisher","first-page":"113506","DOI":"10.1016\/j.bbr.2021.113506","volume":"415","author":"CA Botz-Zapp","year":"2021","unstructured":"Botz-Zapp CA, Foster SL, Pulley DM, Hempel B, Bi G-H, Xi Z-X, Newman AH, Weinshenker D, Manvich DF (2021) Effects of the selective dopamine D3 receptor antagonist PG01037 on morphine-induced hyperactivity and antinociception in mice. Behav Brain Res 415:113506. https:\/\/doi.org\/10.1016\/j.bbr.2021.113506","journal-title":"Behav Brain Res"},{"key":"6093_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejphar.2015.05.067","volume":"761","author":"D Cavalla","year":"2015","unstructured":"Cavalla D, Chianelli F, Korsak A, Hosford PS, Gourine AV, Marina N (2015) Tianeptine prevents respiratory depression without affecting analgesic effect of opiates in conscious rats. Eur J Pharmacol 761:268\u2013272. https:\/\/doi.org\/10.1016\/j.ejphar.2015.05.067","journal-title":"Eur J Pharmacol"},{"key":"6093_CR14","doi-asserted-by":"publisher","first-page":"107101","DOI":"10.1016\/j.vascn.2021.107101","volume":"111","author":"ML Crowley","year":"2021","unstructured":"Crowley ML, Restrepo LF, Gamez-Jimenez LR, Patel A, Braun T, Pallares VLC, Ho NP, Reeves ME, McCurdy CR, McMahon LR, Hiranita T (2021) The use of hypercapnic conditions to assess opioid-induced respiratory depression in rats. J Pharmacol Toxicol Methods 111:107101. https:\/\/doi.org\/10.1016\/j.vascn.2021.107101","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"6093_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jat\/bkx034","volume":"41","author":"SK Dempsey","year":"2017","unstructured":"Dempsey SK, Poklis JL, Sweat K, Cumpston K, Wolf CE (2017) Acute toxicity from intravenous use of the tricyclic antidepressant tianeptine. J Anal Toxicol 41(6):547\u2013550. https:\/\/doi.org\/10.1093\/jat\/bkx034","journal-title":"J Anal Toxicol"},{"issue":"2","key":"6093_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.120.000464","volume":"377","author":"CM Diester","year":"2021","unstructured":"Diester CM, Santos EJ, Moerke MJ, Negus SS (2021) Behavioral battery for testing candidate analgesics in mice I Validation with positive and negative controls. J Pharmacol Exp Ther 377(2):232\u2013241. https:\/\/doi.org\/10.1124\/jpet.120.000464","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"6093_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/0002-9343(71)90298-1","volume":"51","author":"JL Duberstein","year":"1971","unstructured":"Duberstein JL, Kaufman DM (1971) A clinical study of an epidemic of heroin intoxication and heroin-induced pulmonary edema. Am J Med 51(6):704\u2013714. https:\/\/doi.org\/10.1016\/0002-9343(71)90298-1","journal-title":"Am J Med"},{"issue":"30","key":"6093_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.15585\/mmwr.mm6730a2","volume":"67","author":"T El Zahran","year":"2018","unstructured":"El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, Aaron C, King A, Chang A (2018) Characteristics of Tianeptine exposures reported to the national poison data system\u2014United States 2000\u20132017. MMWR Morbidity and Mortality Weekly Report 67(30):815\u2013818. https:\/\/doi.org\/10.15585\/mmwr.mm6730a2","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"issue":"6","key":"6093_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0091-3057(83)90395-7","volume":"19","author":"H-R Frischknecht","year":"1983","unstructured":"Frischknecht H-R, Siegfried B, Riggio G, Waser PG (1983) Inhibition of morphine-induced analgesia and locomotor activity in strains of mice: a comparison of long-acting opiate antagonists. Pharmacol Biochem Behav 19(6):939\u2013944. https:\/\/doi.org\/10.1016\/0091-3057(83)90395-7","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20132","key":"6093_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(93)91608-U","volume":"619","author":"M Funada","year":"1993","unstructured":"Funada M, Suzuki T, Narita M, Misawa M, Nagase H (1993) Modification of morphine-induced locomotor activity by pertussis toxin: biochemical and behavioral studies in mice. Brain Res 619(1\u20132):163\u2013172. https:\/\/doi.org\/10.1016\/0006-8993(93)91608-U","journal-title":"Brain Res"},{"issue":"7","key":"6093_CR21","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1038\/tp.2014.30","volume":"4","author":"MM Gassaway","year":"2014","unstructured":"Gassaway MM, Rives M-L, Kruegel AC, Javitch JA, Sames D (2014) The atypical antidepressant and neurorestorative agent tianeptine is a \u03bc-opioid receptor agonist. Transl Psychiatry 4(7):e411\u2013e411. https:\/\/doi.org\/10.1038\/tp.2014.30","journal-title":"Transl Psychiatry"},{"issue":"12","key":"6093_CR22","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/15563650.2018.1533727","volume":"56","author":"DD Gummin","year":"2018","unstructured":"Gummin DD, Mowry JB, Spyker DA, Brooks DE, Osterthaler KM, Banner W (2018) 2017 annual report of the american association of poison control centers\u2019 National Poison Data System (NPDS): 35th annual report. Clin Toxicol 56(12):1213\u20131415. https:\/\/doi.org\/10.1080\/15563650.2018.1533727","journal-title":"Clin Toxicol"},{"issue":"13","key":"6093_CR23","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/bph.14224","volume":"175","author":"R Hill","year":"2018","unstructured":"Hill R, Disney A, Conibear A, Sutcliffe K, Dewey W, Husbands S, Bailey C, Kelly E, Henderson G (2018) The novel \u03bc-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception: PZM21 depresses respiration. Br J Pharmacol 175(13):2653\u20132661. https:\/\/doi.org\/10.1111\/bph.14224","journal-title":"Br J Pharmacol"},{"issue":"3","key":"6093_CR24","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/npp.2015.201","volume":"41","author":"R Hill","year":"2016","unstructured":"Hill R, Lyndon A, Withey S, Roberts J, Kershaw Y, MacLachlan J, Lingford-Hughes A, Kelly E, Bailey C, Hickman M, Henderson G (2016) Ethanol reversal of tolerance to the respiratory depressant effects of morphine. Neuropsychopharmacology 41(3):762\u2013773. https:\/\/doi.org\/10.1038\/npp.2015.201","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"6093_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bph.14860","volume":"177","author":"R Hill","year":"2020","unstructured":"Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G (2020) Fentanyl depression of respiration: comparison with heroin and morphine. Br J Pharmacol 177(2):254\u2013265. https:\/\/doi.org\/10.1111\/bph.14860","journal-title":"Br J Pharmacol"},{"issue":"S3","key":"6093_CR26","doi-asserted-by":"publisher","first-page":"331s","DOI":"10.1016\/S0924-9338(02)00651-X","volume":"17","author":"S Kasper","year":"2002","unstructured":"Kasper S, Oli\u00e9 JP (2002) A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 17(S3):331s\u2013340s. https:\/\/doi.org\/10.1016\/S0924-9338(02)00651-X","journal-title":"Eur Psychiatry"},{"issue":"6","key":"6093_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.psym.2018.07.006","volume":"59","author":"R Lauhan","year":"2018","unstructured":"Lauhan R, Hsu A, Alam A, Beizai K (2018) Tianeptine abuse and dependence: case report and literature review. Psychosomatics 59(6):547\u2013553. https:\/\/doi.org\/10.1016\/j.psym.2018.07.006","journal-title":"Psychosomatics"},{"key":"6093_CR28","unstructured":"Malen C, Danree B, Poignant J-C (1973)\u00a0Tricyclic compounds (United States Patent Office Patent No. 3,758,528)"},{"issue":"5","key":"6093_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1037\/pha0000042","volume":"23","author":"LL Miller","year":"2015","unstructured":"Miller LL, Altarifi AA, Negus SS (2015) Effects of repeated morphine on intracranial self-stimulation in male rats in the absence or presence of a noxious pain stimulus. Exp Clin Psychopharmacol 23(5):405\u2013414. https:\/\/doi.org\/10.1037\/pha0000042","journal-title":"Exp Clin Psychopharmacol"},{"key":"6093_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuropharm.2019.03.020","volume":"151","author":"MJ Moerke","year":"2019","unstructured":"Moerke MJ, Negus SS (2019) Role of agonist efficacy in exposure-induced enhancement of Mu opioid reward in rats. Neuropharmacology 151:180\u2013188. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.020","journal-title":"Neuropharmacology"},{"issue":"3","key":"6093_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00213-020-05725-3","volume":"238","author":"MJ Moerke","year":"2021","unstructured":"Moerke MJ, Negus SS (2021) Temporal parameters of enhanced opioid reward after initial opioid exposure in rats. Psychopharmacology 238(3):725\u2013734. https:\/\/doi.org\/10.1007\/s00213-020-05725-3","journal-title":"Psychopharmacology"},{"issue":"3","key":"6093_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1124\/pr.112.007419","volume":"66","author":"SS Negus","year":"2014","unstructured":"Negus SS, Miller LL (2014) Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev 66(3):869\u2013917. https:\/\/doi.org\/10.1124\/pr.112.007419","journal-title":"Pharmacol Rev"},{"key":"6093_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.peptides.2018.10.007","volume":"112","author":"SS Negus","year":"2019","unstructured":"Negus SS, Moerke MJ (2019) Determinants of opioid abuse potential: Insights using intracranial self-stimulation. Peptides 112:23\u201331. https:\/\/doi.org\/10.1016\/j.peptides.2018.10.007","journal-title":"Peptides"},{"issue":"15\u201316","key":"6093_CR34","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.lfs.2010.02.013","volume":"86","author":"MD Osborn","year":"2010","unstructured":"Osborn MD, Lowery JJ, Skorput AGJ, Giuvelis D, Bilsky EJ (2010) In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci 86(15\u201316):624\u2013630. https:\/\/doi.org\/10.1016\/j.lfs.2010.02.013","journal-title":"Life Sci"},{"issue":"2\u20133","key":"6093_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.forsciint.2007.03.035","volume":"170","author":"P Proen\u00e7a","year":"2007","unstructured":"Proen\u00e7a P, Teixeira H, Pinheiro J, Monsanto PV, Vieira DN (2007) Fatal intoxication with tianeptine (Stablon\u00ae). Forensic Sci Int 170(2\u20133):200\u2013203. https:\/\/doi.org\/10.1016\/j.forsciint.2007.03.035","journal-title":"Forensic Sci Int"},{"issue":"2","key":"6093_CR36","first-page":"472","volume":"176","author":"CR Rethy","year":"1971","unstructured":"Rethy CR, Smith CB, Villarreal JE (1971) Effects of narcotic analgesics upon the locomotor activity and brain catecholamine content of the mouse. J Pharmacol Exp Ther 176(2):472\u2013479","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"6093_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/jpet.108.143438","volume":"327","author":"GR Ross","year":"2008","unstructured":"Ross GR, Gabra BH, Dewey WL, Akbarali HI (2008) Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther 327(2):561\u2013572. https:\/\/doi.org\/10.1124\/jpet.108.143438","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"6093_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/15563650.2020.1781151","volume":"59","author":"W Rushton","year":"2021","unstructured":"Rushton W, Whitworth B, Brown J, Kurz M, Rivera J (2021) Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health. Clin Toxicol 59(2):152\u2013157. https:\/\/doi.org\/10.1080\/15563650.2020.1781151","journal-title":"Clin Toxicol"},{"issue":"10","key":"6093_CR39","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/npp.2017.60","volume":"42","author":"BA Samuels","year":"2017","unstructured":"Samuels BA, Nautiyal KM, Kruegel AC, Levinstein MR, Magalong VM, Gassaway MM, Grinnell SG, Han J, Ansonoff MA, Pintar JE, Javitch JA, Sames D, Hen R (2017) The behavioral effects of the antidepressant tianeptine require the Mu-opioid receptor. Neuropsychopharmacology 42(10):2052\u20132063. https:\/\/doi.org\/10.1038\/npp.2017.60","journal-title":"Neuropsychopharmacology"},{"key":"6093_CR40","doi-asserted-by":"publisher","unstructured":"Severino AL, Mittal N, Hakimian JK, Velarde N, Minasyan A, Albert R, Torres C, Romaneschi N, Johnston C, Tiwari S, Lee AS, Taylor AM, Gav\u00e9riaux-Ruff C, Kieffer BL, Evans CJ, Cahill CM, Walwyn WM (2020) \u03bc-opioid receptors on distinct neuronal populations mediate different aspects of opioid reward-related behaviors. Eneuro\u00a07(5). https:\/\/doi.org\/10.1523\/ENEURO.0146-20.2020","DOI":"10.1523\/ENEURO.0146-20.2020"},{"key":"6093_CR41","doi-asserted-by":"publisher","unstructured":"Smith KE, Rogers JM, Strickland JC, Epstein DH (2021) When an obscurity becomes trend: Social-media descriptions of tianeptine use and associated atypical drug use. Am J Drug Alcohol Abuse :1\u201312. https:\/\/doi.org\/10.1080\/00952990.2021.1904408","DOI":"10.1080\/00952990.2021.1904408"},{"issue":"S1","key":"6093_CR42","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/ijosup.2014.3","volume":"4","author":"NM Urs","year":"2014","unstructured":"Urs NM, Caron MG (2014) The physiological relevance of functional selectivity in dopamine signalling. Int J Obesity Supplements 4(S1):S5\u2013S8. https:\/\/doi.org\/10.1038\/ijosup.2014.3","journal-title":"Int J Obesity Supplements"},{"key":"6093_CR43","unstructured":"U.S. Food and Drug Administration (2018)\u00a0FDA warns marketers of products labeled as dietary supplements that contain tianeptine for making unproven claims to treat serious conditions, including opioid use disorder. FDA; FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-warns-marketers-products-labeled-dietary-supplements-contain-tianeptine-making-unproven-claims"},{"issue":"2","key":"6093_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/sj.npp.1301143","volume":"32","author":"TI Uzbay","year":"2007","unstructured":"Uzbay TI, Kayir H, Ceyhan M (2007) Effects of Tianeptine on onset time of pentylenetetrazole-induced seizures in mice: possible role of adenosine A1 receptors. Neuropsychopharmacology 32(2):412\u2013416. https:\/\/doi.org\/10.1038\/sj.npp.1301143","journal-title":"Neuropsychopharmacology"},{"key":"6093_CR45","doi-asserted-by":"publisher","first-page":"114805","DOI":"10.1016\/j.bcp.2021.114805","volume":"195","author":"NB Varshneya","year":"2022","unstructured":"Varshneya NB, Hassanien SH, Holt MC, Stevens DL, Layle NK, Bassman JR, Iula DM, Beardsley PM (2022) Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated. Biochem Pharmacol 195:114805. https:\/\/doi.org\/10.1016\/j.bcp.2021.114805","journal-title":"Biochem Pharmacol"},{"key":"6093_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuropharm.2019.03.023","volume":"151","author":"NB Varshneya","year":"2019","unstructured":"Varshneya NB, Walentiny DM, Moisa LT, Walker TD, Akinfiresoye LR, Beardsley PM (2019) Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances. Neuropharmacology 151:171\u2013179. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.023","journal-title":"Neuropharmacology"},{"key":"6093_CR47","doi-asserted-by":"publisher","first-page":"173242","DOI":"10.1016\/j.pbb.2021.173242","volume":"208","author":"NB Varshneya","year":"2021","unstructured":"Varshneya NB, Walentiny DM, Moisa LT, Walker TD, Akinfiresoye LR, Beardsley PM (2021) Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors. Pharmacol Biochem Behav 208:173242. https:\/\/doi.org\/10.1016\/j.pbb.2021.173242","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"6093_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00023210-200115030-00006","volume":"15","author":"AJ Wagstaff","year":"2001","unstructured":"Wagstaff AJ, Ormrod D, Spencer CM (2001) Tianeptine: a review of its use in depressive disorders. CNS Drugs 15(3):231\u2013259. https:\/\/doi.org\/10.2165\/00023210-200115030-00006","journal-title":"CNS Drugs"},{"issue":"suppl 1","key":"6093_CR49","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1111\/pme.12911","volume":"16","author":"LR Webster","year":"2015","unstructured":"Webster LR (2015) Opioid-induced constipation. Pain Med 16(suppl 1):S16\u2013S21. https:\/\/doi.org\/10.1111\/pme.12911","journal-title":"Pain Med"},{"issue":"3","key":"6093_CR50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00003495-199549030-00007","volume":"49","author":"MI Wilde","year":"1995","unstructured":"Wilde MI, Benfield P (1995) Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 49(3):411\u2013439. https:\/\/doi.org\/10.2165\/00003495-199549030-00007","journal-title":"Drugs"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06093-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T09:11:30Z","timestamp":1655457090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06093-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6093"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06093-w","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The opinions, findings, and conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of the National Institutes of Health or the Department of Justice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}